Navigation Links
Kitov Pharmaceuticals to Announce Interim Results of the Pivotal Phase III Trial on December 15, 2015 at 7:00am ET
Date:12/10/2015

TEL AVIV, Dec. 10, 2015 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (TASE: KTOV), a biopharmaceutical company focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions, today announced it expects to have received the completed statistical analysis, and to publish the interim results from its recently concluded pivotal Phase III trial of its combination drug candidate KIT-302 at 7:00am ET on Tuesday, December 15, 2015. In conjunction with the release of the anticipated announcement, Kitov management will hold a press conference at 2:00pm local time in Tel Aviv, Israel at the Hilton Tel Aviv Hotel. The press conference will be webcast live and a playback will be available at www.kitovpharma.com.  The link for the live webcast together with an updated company presentation will be published together with interim results.

The Phase III trial, conducted under the auspices of the U.S. Food & Drug Administration, is evaluating Kitov's lead drug candidate KIT-302 for the treatment of high blood pressure and pain caused by osteoarthritis. KIT-302 is a combination drug comprised of two drugs that are already FDA-approved, amlodipine besylate for the reduction of high blood pressure and celecoxib for reduction of pain caused by osteoarthritis.

About Kitov Pharmaceuticals Holdings Ltd.
Kitov Pharmaceuticals Holdings Ltd. is a biopharmaceutical company focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions. In particular, Kitov focuses on developing combinations of existing drugs in advanced stages of development. Kitov's lead drug, KIT-302, is formulated for the simultaneous treatment of two clinical conditions – pain caused by osteoarthritis (OA) and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for OA. KIT-302 is based on celecoxib, the active ingredient of a known and approved-for-use drug designed primarily to relieve pain caused by OA, and the generic drug amlodipine besylate. Kitov is traded on the Nasdaq Capital Market (Nasdaq: KTOV) and the Tel-Aviv Stock Exchange (TASE: KTOV).

Forward-Looking Statements
This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements involve certain risks and uncertainties, including, among others, risks impacting the ability of the Company to complete any public offering of its securities because of general market conditions or other factors and risks that could cause the Company's results to differ materially from those expected by Company management. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Kitov Pharmaceuticals Holdings Ltd.'s Registration Statement on Form F-1 filed with the SEC, which is available on the SEC's website, www.sec.gov.

Contact:

Simcha Rock, CFO
+972-2-6254124
Simcha@kitovpharma.com


'/>"/>
SOURCE Kitov
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
2. Kitov Pharmaceuticals Holdings Announces Closing of U.S. Initial Public Offering
3. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
4. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
5. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
6. Access Pharmaceuticals Reports First Quarter Results
7. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
8. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
9. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
10. Aveo Pharmaceuticals, Inc. Sued by Investor
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2020)... ... 2020 , ... Terry Moore, a renowned business leader and popular TED speaker ... ™ and the company’s Beacon40 ™ product line. Singularly focused on bringing hope ... that designs wellness products based on cutting-edge scientific research. With the CDC calling ...
(Date:2/10/2020)... ... 2020 , ... Soter Technologies, the company that created FlySense™ ... in the world for schools, has announced a new strategic partnership with ... for schools, cities, and law enforcement. The first deployment of the combined technology ...
(Date:2/10/2020)... ... February 10, 2020 , ... The Relapsing Polychondritis Foundation is pleased to ... GT driver, will be a Race for RP driver in 2020. Mia is ... polychondritis (RP) and other autoimmune diseases. , Flewitt has spent the past three decades ...
Breaking Medicine Technology:
(Date:2/14/2020)... ... 2020 , ... The Dr. Oz Show is an American daytime television talk ... medical information. As an upcoming guest on the show, New York City plastic ... medical knowledge. During the segment, Dr. Linkov, a leader and trusted authority on hair ...
(Date:2/13/2020)... ... 13, 2020 , ... The Root Cause Coalition, representing 77 ... for all Americans will unveil its new Status of Health Equity Report and ... Press Club. , The event will feature a presentation and discussion of the ...
(Date:2/13/2020)... ... February 13, 2020 , ... President Trump recently ... budget proposes substantial, damaging cuts to foreign affairs, global health, and global child ... diplomacy, slashes USAID global health programs by $3.1B, and significantly reduces funding for ...
(Date:2/11/2020)... (PRWEB) , ... February 11, 2020 , ... ... affairs services and solutions, today announced its move to a new, significantly larger ... global customer base alongside significant expansion in the development of digital technology platforms. ...
(Date:2/11/2020)... ... February 11, 2020 , ... This week ... Edition: From Sourcing to Butchery, Mindful Meat Eating for the Modern Omnivore . ... Society Publishers, this new version brings discussions of responsible meat production, consumption, and ...
Breaking Medicine News(10 mins):